Norah G Verbout

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 6

Top Topics

Pulmonary Embolism

Lipopolysaccharide Induced

Top Venues

Communications medicine

Metabolic brain disease

This page only lists publications with an associated author ORCID identifier.

Publications

Norah G Verbout, Christina U Lorentz, Brandon D Markway, Michael Wallisch, Thomas C Marbury, Enrico Di Cera, Joseph J Shatzel, András Gruber, Erik I Tucker
Safety and tolerability of the protein C activator AB002 in end-stage renal disease patients on hemodialysis: a randomized phase 2 trial. Communications medicine 4 (1) (2024)
Norah G Verbout, Christina U Lorentz, Brandon D Markway, Michael Wallisch, Thomas C Marbury, Enrico Di Cera, Joseph J Shatzel, András Gruber, Erik I Tucker
Safety and tolerability of the protein C activator AB002 in end-stage renal disease patients on hemodialysis: a randomized phase 2 trial. Communications medicine 4 (1) (2024)
Norah G Verbout, Christina U Lorentz, Brandon D Markway, Michael Wallisch, Thomas C Marbury, Enrico Di Cera, Joseph J Shatzel, András Gruber, Erik I Tucker
Safety and tolerability of the protein C activator AB002 in end-stage renal disease patients on hemodialysis: a randomized phase 2 trial. Communications medicine 4 (1) (2024)
Norah G Verbout, Christina U Lorentz, Brandon D Markway, Michael Wallisch, Thomas C Marbury, Enrico Di Cera, Joseph J Shatzel, András Gruber, Erik I Tucker
Safety and tolerability of the protein C activator AB002 in end-stage renal disease patients on hemodialysis: a randomized phase 2 trial. Communications medicine 4 (1) (2024)
Tia C L Kohs, Meghan E Fallon, Ethan C Oseas, Laura D Healy, Erik I Tucker, David Gailani, Owen J T McCarty, Arthur A Vandenbark, Halina Offner, Norah G Verbout
Pharmacological targeting of coagulation factor XI attenuates experimental autoimmune encephalomyelitis in mice. Metabolic brain disease (2023)
Christina U Lorentz, Erik I Tucker, Norah G Verbout, Joseph J Shatzel, Sven R Olson, Brandon D Markway, Michael Wallisch, Martina Ralle, Monica T Hinds, Owen J T McCarty, David Gailani, Jeffrey I Weitz, András Gruber
The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial. Blood 138 (22) (2022)